NYSE · Common Stock · Pharmaceutical Preparations
American pharmaceutical company
148 entities across 48 jurisdictions, 7 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-12 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Adverum Biotechnologies, Inc. | Delaware | |
| Adverum NC, LLC | Delaware | |
| Akouos, Inc. | Delaware | |
| Alnara Pharmaceuticals, Inc. | Delaware | |
| Annapurna Therapeutics, Ltd. | Ireland | |
| Aparito Espanya S.L. | Spain | |
| Aparito Limited | United Kingdom | |
| Aparito LLC | Delaware | |
| ARMO Biosciences, Inc. | Delaware | |
| Avalanche Australia Pty Ltd. | Australia | |
| Avid Radiopharmaceuticals, Inc. | Delaware | |
| CoLucid Pharmaceuticals, Inc. | Delaware | |
| CPD 4, Inc. | Delaware | |
| Dermira, Inc. | Delaware | |
| DICE Alpha Inc. | Delaware | |
| DICE Molecules SV, Inc. | Delaware | |
| DICE Therapeutics, Inc. | Delaware | |
| Disarm Therapeutics Inc. | Delaware | |
| Dista Ilac Ticaret Limited Sirketi | Turkey | |
| Dista, S.A. | Spain | |
| Dista-Produtos Quimicos & Farmaceuticos, LDA | Portugal | |
| ELC EHS, LLC | Indiana | |
| ELCO for Trading and Marketing, S.A.E. | Egypt | |
| ELCO Insurance Company Limited | Bermuda | offshore centre |
| ELCO Management, Inc. | Delaware | |
| ELGO Insurance Company Limited | Bermuda | offshore centre |
| Eli Lilly (Malaysia) Sdn. Bhd. | Malaysia | |
| Eli Lilly (S.A.) (Proprietary) Limited | South Africa | |
| Eli Lilly (Singapore) Pte. Ltd. | Singapore | |
| Eli Lilly (Suisse) S.A. | Switzerland | |
| Eli Lilly and Company (India) Pvt. Ltd. | India | |
| Eli Lilly and Company (Ireland) Limited | Ireland | |
| Eli Lilly and Company (N.Z.) Limited | New Zealand | |
| Eli Lilly and Company (Taiwan), Inc. | Taiwan | |
| Eli Lilly and Company Limited | United Kingdom | |
| Eli Lilly Asia Pacific SSC Sdn Bhd | Malaysia | |
| Eli Lilly Asia, Inc. | Delaware | |
| Eli Lilly Australia Pty. Limited | Australia | |
| Eli Lilly Benelux S.A. | Belgium | |
| Eli Lilly Bienes y Servicios S. de R.L. de C.V. | Mexico | |
| Eli Lilly Canada Inc. | Canada | |
| Eli Lilly Clinical Diagnostics Laboratory LLC | Indiana | |
| Eli Lilly Cork Limited | Ireland | |
| Eli Lilly CR s.r.o. | Czech Republic | |
| Eli Lilly Danmark A/S | Denmark | |
| Eli Lilly do Brasil Limitada | Brazil | |
| Eli Lilly Drug Store LLC | United Arab Emirates | |
| Eli Lilly Egypt for Trading Company S.A.E. | Egypt | |
| Eli Lilly European Clinical Trial Services S.A. | Belgium | |
| Eli Lilly Export S.A. | Switzerland | |
| Eli Lilly Finance, S.A. | Switzerland | |
| Eli Lilly Ges.m.b.H. | Austria | |
| Eli Lilly Group Limited | United Kingdom | |
| Eli Lilly Interamerica Inc., y Compania Limitada | Chile | |
| Eli Lilly Interamerica, Inc. | Indiana | |
| Eli Lilly International Corporation | Indiana | |
| Eli Lilly Ireland Holdings Limited | Ireland | |
| Eli Lilly Israel Ltd. | Israel | |
| Eli Lilly Italia S.p.A. | Italy | |
| Eli Lilly Japan K.K. | Japan | |
| Eli Lilly Kinsale Limited | Ireland | |
| Eli Lilly Nederland B.V. | Netherlands | |
| Eli Lilly Norge A.S. | Norway | |
| Eli Lilly Pakistan (Pvt.) Ltd. | Pakistan | |
| Eli Lilly Polska Sp. z.o.o. (Ltd.) | Poland | |
| Eli Lilly Regional Operations GmbH | Austria | |
| Eli Lilly Romania S.R.L. | Romania | |
| Eli Lilly S.A. | Switzerland | |
| Eli Lilly Saudi Arabia Limited | Saudi Arabia | |
| Eli Lilly Services India Private Limited | India | |
| Eli Lilly Services Peru S.A.C | Peru | |
| Eli Lilly Sweden AB | Sweden | |
| Eli Lilly Vostok S.A. | Switzerland | |
| Eli Lilly y Compania de Mexico, S.A. de C.V. | Mexico | |
| Emergence Therapeutics France SAS | France | |
| Glycostasis, Inc. | Delaware | |
| Greenfield-Produtos Farmaceuticos, Lda. | Portugal | |
| ICOS Corporation | Washington | |
| ImClone LLC | Delaware | |
| ImClone Systems Holdings, Inc. | Delaware | |
| Irisfarma S.A. | Spain | |
| Isopro Holdings LLC | Delaware | |
| LDH I Corporation | Delaware | |
| LDH II Corporation | Delaware | |
| LDH III Corporation | Delaware | |
| LDH IV Corporation | Delaware | |
| LDH V 2023 Corporation | Delaware | |
| LDH VI Corporation | Delaware | |
| LDH VII Corporation | Delaware | |
| LDH VIII Corporation | Delaware | |
| Lilly (Beijing) Medical Tech Innovation Co., Ltd. | China | |
| Lilly (Shanghai) Management Co., Ltd. | China | |
| Lilly Asia Ventures Fund I, L.P. | Cayman Islands | offshore centre |
| Lilly Asia Ventures Fund II, L.P. | Cayman Islands | offshore centre |
| Lilly Asian Ventures Fund III, L.P. | Cayman Islands | offshore centre |
| Lilly Cayman Holdings | Cayman Islands | offshore centre |
| Lilly Centre for Clinical Pharmacology PTE. LTD. | Singapore | |
| Lilly China Research and Development Co., Ltd | China | |
| Lilly del Caribe, Inc. | Cayman Islands | offshore centre |
| Lilly Deutschland GmbH | Germany | |
| Lilly France S.A.S. | France | |
| Lilly Global Nederland Holdings B.V. | Netherlands | |
| Lilly Global Services, Inc. | Indiana | |
| Lilly Holding GmbH | Germany | |
| Lilly Holdings B.V. | Netherlands | |
| Lilly Hungaria KFT | Hungary | |
| Lilly Ilac Ticaret Limited Sirketi | Turkey | |
| Lilly Japan Financing G.K. | Japan | |
| Lilly Korea Ltd. | Korea | |
| Lilly Lebanon Advanced Therapies LLC | Indiana | |
| Lilly Nederland Finance B.V. | Netherlands | |
| Lilly Nederland Holding B.V. | Netherlands | |
| Lilly Pharma Ltd. | Russia | |
| Lilly Portugal - Produtos Farmaceuticos, Lda. | Portugal | |
| Lilly S.A. | Spain | |
| Lilly Suzhou Pharmaceutical Co. Ltd. | China | |
| Lilly Trading Co. LTD | China | |
| Lilly USA, LLC | Indiana | |
| Lilly Ventures Fund I LLC | Delaware | |
| LillyDirect Pharmacy, LLC | Delaware | |
| Loxo Oncology, Inc. | Delaware | |
| Mablink Bioscience S.A.S. | France | |
| Manet Holdings LLC | Delaware | |
| Morphic Holding, Inc. | Delaware | |
| Morphic Therapeutic UK Ltd. | United Kingdom | |
| Morphic Therapeutic, Inc. | Delaware | |
| NexPharm Parent Holdco, LLC | Delaware | |
| OY Eli Lilly Finland AB | Finland | |
| Pandinus MSC, Inc. | Massachusetts | |
| Petra Pharma Corporation | Delaware | |
| Pharmaserve-Lilly S.A.C.I. | Greece | |
| Point Biopharma Corp. | Canada | |
| Point Biopharma Global Inc. | Delaware | |
| Point Biopharma Inc. | Delaware | |
| Point Biopharma USA Inc. | Delaware | |
| Prevail Therapeutics Inc. | Delaware | |
| Protomer Technologies, Inc. | Delaware | |
| Scorpion Therapeutics, Inc. | Delaware | |
| SGX Pharmaceuticals, Inc. | Delaware | |
| Sigilon Therapeutics Inc. | Delaware | |
| SiteOne Therapeutics, Inc. | Delaware | |
| Spaly Bioquimica, S.A. | Spain | |
| Valquifarma, S.A. | Spain | |
| Versanis Bio Australia PTY LTD | Australia | |
| Versanis Bio, Inc. | Delaware | |
| Verve Therapeutics, Inc. | Delaware | |
| Victoria Holdco Corp. | Delaware | |
| Vitalfarma - Produtos Farmaceuticos, Lda. | Portugal |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $24.5B | $6.2B | — | — | 912,505,000 |
| FY2021 | $28.3B | $5.6B | — | — | 911,681,000 |
| FY2022 | $28.5B | $6.2B | — | — | 904,619,000 |
| FY2023 | $34.1B | $5.2B | — | — | 903,284,000 |
| FY2024 | $45.0B | $10.6B | — | — | 904,059,000 |
| FY2025 | $65.2B | $20.6B | — | — | 899,300,000 |
18 institutions tracked — 11 added, 5 reduced, 1 opened a new position.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 10,998,953 | −2,428,108 | $13.2B |
| FMR LLC | Active fund | 28,462,475 | +2,121,444 | $34.1B |
| CITADEL ADVISORS LLC | Hedge fund | 5,176,156 | +1,631,542 | $6.2B |
| JPMORGAN CHASE & CO | Active fund | 13,121,824 | −1,162,967 | $16.1B |
| BlackRock, Inc. | Index | 67,540,400 | +1,046,558 | $81.0B |
| MORGAN STANLEY | Active fund | 16,226,398 | +788,940 | $19.5B |
| STATE STREET CORP | Index | 36,215,754 | +605,752 | $43.4B |
| Capital World Investors | Active fund | 15,902,642 | +280,829 | $19.1B |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,035,605 | +180,185 | $1.2B |
| BANK OF AMERICA CORP /DE/ | Active fund | 11,274,243 | +148,411 | $13.5B |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 20,310,858 | +118,994 | $24.3B |
| Point72 Asset Management, L.P. | Hedge fund | 76,876 | −80,790 | $92.2M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 13,911,839 | −80,385 | $16.7M |
| ARK Investment Management LLC | Active fund | 77,254 | +64,578 | $92.7M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 26,091 | −45,697 | $31.3M |
| Bridgewater Associates, LP | Hedge fund | 87,023 | +16,211 | $104.4M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
ELI LILLY & Co files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
